PE20050628A1 - DERIVADOS DE 2-AMINO-PIRIDINA COMO AGONISTAS ß-2 - Google Patents
DERIVADOS DE 2-AMINO-PIRIDINA COMO AGONISTAS ß-2Info
- Publication number
- PE20050628A1 PE20050628A1 PE2004000553A PE2004000553A PE20050628A1 PE 20050628 A1 PE20050628 A1 PE 20050628A1 PE 2004000553 A PE2004000553 A PE 2004000553A PE 2004000553 A PE2004000553 A PE 2004000553A PE 20050628 A1 PE20050628 A1 PE 20050628A1
- Authority
- PE
- Peru
- Prior art keywords
- amino
- phenyl
- pyridin
- alkyl
- pyridine derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A DERIVADOS DE 2-AMINO-PIRIDINA DE FORMULA (I) DONDE EL GRUPO (CH2)n-C(=O)Q1 ESTA EN LA POSICION META O PARA; R1 Y R2 SON INDEPENDIENTEMENTE H Y ALQUILO(C1-C4), n ES DE 0 A 2, Q1 ES UN GRUPO DE FORMULA a), b), c) Y *-NR-Q2-A, DONDE p ES DE 1 A 3; q ES 1 O 2, Q2 ES UN ENLACE DIRECTO O ALQUILENO(C1-C4); R ES H, ALQUILO(C1-C4) O FENILO; A ES CICLOALQUILO(C3-C7), TETRAHIDROPIRANILO, PIPERIDINILO, O UN FENILO OPCIONALMENTE SUSTITUIDO CON H, ALQUILO(C1-C4), OR9, SR9, HALOGENO ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 2-(3-{(2R)-2-[(2R)-2-(6-AMINO-PIRIDIN-3-IL)-2-HIDROXI-ETILAMINO]-PROPIL}-FENIL)-N-BENCIL-ACETAMIDA, 2-(4-{2-[(2R)-2-(6-AMINO-PIRIDIN-3-IL)-2-HIDROXI-ETILAMINO]-2-METIL-PROPIL]-FENIL)-N-(2,6-DIMETOXI-BENCIL)-ACETAMIDA, 3-(2-{(2R)-2-[6-(2,5-DIMETILPIRROL-1-IL)PIRIDIN-3-IL]-2-HIDROXIETILAMINO}-2-METILPROPIL)-N-(4'-HIDROXIBIFENIL-3-ILMETIL)BENZAMINA, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE ELABORACION Y UNA COMPOSICION FARMACEUTICA. ESTOS COMPUESTOS TIENEN UNA ACTIVIDAD AGONISTA BETA-2, POR LOS QUE SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES, TRANSTORNOS Y AFECCIONES INFLAMATORIAS ALERGICAS Y RESPIRATORIAS
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0312832.9A GB0312832D0 (en) | 2003-06-04 | 2003-06-04 | 2-amino-pyridine derivatives useful for the treatment of diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20050628A1 true PE20050628A1 (es) | 2005-08-30 |
Family
ID=9959308
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2004000553A PE20050628A1 (es) | 2003-06-04 | 2004-06-01 | DERIVADOS DE 2-AMINO-PIRIDINA COMO AGONISTAS ß-2 |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP1633715B1 (es) |
JP (1) | JP2006526613A (es) |
AR (1) | AR044475A1 (es) |
AT (1) | ATE372321T1 (es) |
BR (1) | BRPI0410946A (es) |
CA (1) | CA2527788A1 (es) |
CL (1) | CL2004001366A1 (es) |
DE (1) | DE602004008773T2 (es) |
ES (1) | ES2291882T3 (es) |
GB (1) | GB0312832D0 (es) |
GT (1) | GT200400116A (es) |
MX (1) | MXPA05012840A (es) |
NL (1) | NL1026329C2 (es) |
PA (1) | PA8604301A1 (es) |
PE (1) | PE20050628A1 (es) |
TW (1) | TW200524603A (es) |
UY (1) | UY28339A1 (es) |
WO (1) | WO2004108676A1 (es) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
PE20060272A1 (es) | 2004-05-24 | 2006-05-22 | Glaxo Group Ltd | (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a |
UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
CA2580787A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes |
CN101083992A (zh) | 2004-09-20 | 2007-12-05 | 泽农医药公司 | 抑制人硬脂酰CoA去饱和酶的哒嗪衍生物 |
AR051092A1 (es) | 2004-09-20 | 2006-12-20 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa |
TW200626138A (en) | 2004-09-20 | 2006-08-01 | Xenon Pharmaceuticals Inc | Heterocyclic derivatives and their use as therapeutic agents |
MX2007003327A (es) | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa. |
EP2269610A3 (en) | 2004-09-20 | 2011-03-09 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
AU2005286648A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
CA2618646A1 (en) | 2005-06-03 | 2007-11-15 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors |
GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
EP1924553A1 (en) | 2005-08-08 | 2008-05-28 | Argenta Discovery Limited | Bicyclo[2.2.]hept-7-ylamine derivatives and their uses |
GB0516313D0 (en) | 2005-08-08 | 2005-09-14 | Argenta Discovery Ltd | Azole derivatives and their uses |
EP2532677A1 (en) | 2005-10-21 | 2012-12-12 | Novartis AG | Human antibodies against il13 and therapeutic uses |
GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
PL2322525T3 (pl) | 2006-04-21 | 2014-03-31 | Novartis Ag | Pochodne puryny do zastosowania jako agoniści receptora adenozyny A<sub>2A</sub> |
CA2654244A1 (en) * | 2006-06-09 | 2007-12-21 | Parion Sciences, Inc. | Phenyl substituted pyrazinoylguanidine sodium channel blockers possessing beta agonist activity |
WO2008050732A1 (fr) | 2006-10-23 | 2008-05-02 | Takeda Pharmaceutical Company Limited | Dérivé de l'iminopyridine et son utilisation |
PL2155721T3 (pl) | 2007-05-07 | 2011-07-29 | Novartis Ag | Związki organiczne |
PT2444120T (pt) | 2007-12-10 | 2018-01-03 | Novartis Ag | Análogos da amilorida espirocíclicos como bloqueadores de enac |
KR20100113557A (ko) | 2008-01-11 | 2010-10-21 | 노파르티스 아게 | 키나제 억제제로서의 피리미딘 |
US8481569B2 (en) | 2008-04-23 | 2013-07-09 | Takeda Pharmaceutical Company Limited | Iminopyridine derivatives and use thereof |
AU2009256645A1 (en) | 2008-06-10 | 2009-12-17 | Novartis Ag | Pyrazine derivatives as epithelial sodium channel blockers |
US8236786B2 (en) | 2008-08-07 | 2012-08-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
DE102008049675A1 (de) | 2008-09-30 | 2010-04-01 | Markus Dr. Heinrich | Verfahren zur Herstellung von 3-Aminobiphenylen |
PT2379507E (pt) | 2008-12-30 | 2014-01-21 | Pulmagen Therapeutics Inflammation Ltd | Compostos de sulfonamida para o tratamento de desordens respiratórias |
WO2010150014A1 (en) | 2009-06-24 | 2010-12-29 | Pulmagen Therapeutics (Inflammation) Limited | 5r- 5 -deuterated glitazones for respiratory disease treatment |
EP2813227A1 (en) | 2009-10-22 | 2014-12-17 | Vertex Pharmaceuticals Incorporated | Compositions for treatment of cystic fibrosis and other chronic diseases |
GB0918924D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Azaindole derivatives |
GB0918922D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminopyridine derivatives |
GB0918923D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminothiazole derivatives |
WO2011098746A1 (en) | 2010-02-09 | 2011-08-18 | Pulmagen Therapeutics (Inflammation) Limited | Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone |
GB201002224D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
GB201002243D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
US9102671B2 (en) | 2011-02-25 | 2015-08-11 | Novartis Ag | Compounds and compositions as TRK inhibitors |
US8883819B2 (en) | 2011-09-01 | 2014-11-11 | Irm Llc | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension |
WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
ES2558457T3 (es) | 2011-09-16 | 2016-02-04 | Novartis Ag | Compuestos heterocíclicos para el tratamiento de fibrosis quística |
WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
EP2755652B1 (en) | 2011-09-16 | 2021-06-02 | Novartis AG | N-substituted heterocyclyl carboxamides |
US8809340B2 (en) | 2012-03-19 | 2014-08-19 | Novartis Ag | Crystalline form |
US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
KR20160141856A (ko) | 2014-04-24 | 2016-12-09 | 노파르티스 아게 | 포스파티딜이노시톨 3-키나제 억제제로서의 피라진 유도체 |
PT3134396T (pt) | 2014-04-24 | 2019-12-16 | Novartis Ag | Derivados de amino piridina como inibidores da fosfatidilinositol 3-quinase |
CN106458979B (zh) | 2014-04-24 | 2020-03-27 | 诺华股份有限公司 | 作为磷脂酰肌醇3-激酶抑制剂的氨基吡嗪衍生物 |
WO2020250116A1 (en) | 2019-06-10 | 2020-12-17 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis |
JOP20220044A1 (ar) | 2019-08-28 | 2023-01-30 | Novartis Ag | مشتقات 1، 3- فينيل أريل غير متجانسة بها استبدال واستخدامها في معالجة مرض |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4358455A (en) * | 1980-12-23 | 1982-11-09 | Merck & Co., Inc. | Aralkylamindethanol heterocyclic compounds |
JPH11504649A (ja) * | 1995-05-10 | 1999-04-27 | ファイザー・インコーポレーテッド | β−アドレナリン作働性アゴニスト |
ES2228413T3 (es) * | 1999-07-23 | 2005-04-16 | Pfizer Products Inc. | Productos intermedios y un procedimiento para producir agonistas de receptores beta-adrenergicos. |
TWI249515B (en) * | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
GB0217225D0 (en) * | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
MXPA05003866A (es) * | 2002-10-11 | 2005-06-22 | Pfizer | Derivados de indol como agonistas beta-2. |
-
2003
- 2003-06-04 GB GBGB0312832.9A patent/GB0312832D0/en not_active Ceased
-
2004
- 2004-06-01 DE DE602004008773T patent/DE602004008773T2/de not_active Expired - Fee Related
- 2004-06-01 MX MXPA05012840A patent/MXPA05012840A/es unknown
- 2004-06-01 ES ES04735621T patent/ES2291882T3/es not_active Expired - Lifetime
- 2004-06-01 EP EP04735621A patent/EP1633715B1/en not_active Expired - Lifetime
- 2004-06-01 CA CA002527788A patent/CA2527788A1/en not_active Abandoned
- 2004-06-01 JP JP2006508431A patent/JP2006526613A/ja not_active Withdrawn
- 2004-06-01 WO PCT/IB2004/001850 patent/WO2004108676A1/en active IP Right Grant
- 2004-06-01 AT AT04735621T patent/ATE372321T1/de not_active IP Right Cessation
- 2004-06-01 BR BRPI0410946-5A patent/BRPI0410946A/pt not_active IP Right Cessation
- 2004-06-01 PE PE2004000553A patent/PE20050628A1/es not_active Application Discontinuation
- 2004-06-02 UY UY28339A patent/UY28339A1/es not_active Application Discontinuation
- 2004-06-03 NL NL1026329A patent/NL1026329C2/nl not_active IP Right Cessation
- 2004-06-03 TW TW093115990A patent/TW200524603A/zh unknown
- 2004-06-03 CL CL200401366A patent/CL2004001366A1/es unknown
- 2004-06-03 GT GT200400116A patent/GT200400116A/es unknown
- 2004-06-03 AR ARP040101904A patent/AR044475A1/es unknown
- 2004-06-03 PA PA20048604301A patent/PA8604301A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
TW200524603A (en) | 2005-08-01 |
DE602004008773D1 (de) | 2007-10-18 |
ATE372321T1 (de) | 2007-09-15 |
ES2291882T3 (es) | 2008-03-01 |
EP1633715B1 (en) | 2007-09-05 |
GT200400116A (es) | 2005-03-03 |
GB0312832D0 (en) | 2003-07-09 |
PA8604301A1 (es) | 2004-12-16 |
BRPI0410946A (pt) | 2006-06-27 |
EP1633715A1 (en) | 2006-03-15 |
DE602004008773T2 (de) | 2008-01-10 |
UY28339A1 (es) | 2005-01-31 |
CA2527788A1 (en) | 2004-12-16 |
JP2006526613A (ja) | 2006-11-24 |
AR044475A1 (es) | 2005-09-14 |
NL1026329C2 (nl) | 2005-07-26 |
WO2004108676A1 (en) | 2004-12-16 |
MXPA05012840A (es) | 2006-02-13 |
CL2004001366A1 (es) | 2005-05-06 |
NL1026329A1 (nl) | 2004-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20050628A1 (es) | DERIVADOS DE 2-AMINO-PIRIDINA COMO AGONISTAS ß-2 | |
RU2324687C2 (ru) | Производные бензотиазола, характеризующиеся агонистической активностью к бета-2-адренорецепторам | |
PE20061150A1 (es) | Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1) | |
PE20081263A1 (es) | DERIVADOS DE 4-(2-AMINO-1-HIDROXIETIL)FENOL COMO AGONISTAS DEL RECEPTOR ß2 ADRENERGICO | |
DE602005019043D1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung | |
PE20060693A1 (es) | Nuevos derivados de trifluorometansulfonanilida oxamida eter | |
PE20061163A1 (es) | Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos | |
DE602006012725D1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung | |
JP2011513196A (ja) | ドーパミン作動系が破壊された障害もしくは状態の症状を軽減するためまたはその障害もしくは状態を処置するためのkcnqカリウムチャネル開口薬の使用 | |
PE20120305A1 (es) | Compuestos heterociclicos derivados de benzotiazol y tetrahidroquinolina como inhbidores de bcl-2 y bcl-xl | |
CL2023001738A1 (es) | Inhibidores de prmt5 | |
RU2014113679A (ru) | N-(2-амино-6,6-дифтор-4,4а,5,6,7,7а-гексагидро-циклопента[e][1,3]оксазин-4-ил)-фенил)-амиды в качестве ингибиторов бета-секретазы 1 | |
UY29766A1 (es) | Formas cristalinas delta y épsilon de mesilato de imatinib | |
PE20110588A1 (es) | Derivados de benzotiazol como agentes anticancerigenos | |
PE20142316A1 (es) | DERIVADOS DE SULFONAMIDA COMO AGENTES INDUCTORES DE APOPTOSIS CON SELECTIVIDAD POR Bcl-2 PARA EL TRATAMIENTO DE CANCER Y ENFERMEDADES INMUNES | |
PE20090547A1 (es) | DERIVADOS DE PIRAZINONA COMO INHIBIDORES DE p38 QUINASA | |
AR072490A1 (es) | 1,2,5- oxadiazoles como inhibidores de indolamina 2,3 dioxigenasa | |
PE20091204A1 (es) | Derivados de 2-aminoquinolina como antagonistas del receptor de 5-ht5a | |
AR052313A1 (es) | Composiciones fungicidas | |
PE20121510A1 (es) | Isoquinolinonas y quinazolinonas sustituidas | |
PE20061098A1 (es) | COMPUESTOS IMIDAZO[1,2-a] PIRIDINILO COMO INHIBIDORES DE VEGF-R2 | |
ATE445609T1 (de) | Substituierte thiophenderivate als glucagonrezeptorantagonisten, herstellung und therapeutische anwendungen | |
PE20060357A1 (es) | Compuestos y composiciones como moduladores de receptor activado de proliferador de peroxisoma (ppar) | |
DE602006015509D1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung | |
BRPI0515261A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso do composto quìmico ou de qualquer um de seus isÈmeros ou de qualquer mistura de seus isÈmeros, ou um sal farmaceuticamente aceitável do mesmo, e, método para o tratamento, a prevenção ou o alìvio de uma doença ou de um distúrbio ou de uma condição de um corpo de animal vivo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |